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ABST RACT
The current treatment of Attention Deficit Disorder and Attention
Deficit with Hyperactivity consists mainly in the administration of
Straterra (Atomoxetine) Concerta and Ritalin (Methylphenidate). The
FDA warned that the products might increase systolic, diastolic blood
pressure, and lead to ventricular arrhythmias. Arrhythmic events and
sudden cardiac death were described in adults with preexistent heart
disease. However, studies on children have failed to demonstrate a clear
association between the arrhythmic events and these drugs, as
demonstrated in adults. What should the attitude of the pediatric
psychiatrist be towards the administration of these products? What
examination should be made by the psychiatrist before referring the child
to a pediatric cardiologist? Which patients need a cardiology
consultation before the administration of these products? What is the
follow-up after drug initiation? These are some questions that this paper
aims to answer.

Introduction
Attention deficit, with or without hyperactivity is a
common condition during childhood, affecting 5% of the
children [1,2]. This condition poses problems regarding the
child’s adaptation to social life and educational activity
during kindergarten, school or high-school. The most
effective drugs in the treatment of these conditions are
psychostimulants such as methylphenidate and nonstimulants: Atomoxetine [3,4], two drugs that have a
phenyl-piperidine and phenyl-propane structure (Figure 1).
Methylphenidate induces the release of norepinephrine and
dopamine at the synaptic level and stimulates postsynaptic
receptors (Figure 2), and Atomoxetine is a selective
inhibitor of norepinephrine re-uptake (Figure 3). Increased
plasma catecholamines will increase cardiac inotropism
and heart rate through a beta-1 adrenergic effect and
increase blood pressure through an alpha-adrenergic effect.
In 2006, the FDA issued a major warning on
psychostimulants that they can increase blood pressure and
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drew attention to other cardiac side effects such as
ventricular arrhythmias and sudden cardiac death. For
these reasons, the contraindication of psychostimulants has
been formulated in children with known arrhythmias or
known heart diseases such as congenital heart diseases,
acquired
myocarditis,
dilated
or
hypertrophic
cardiomyopathy. However, serious studies published in the
New England Journal of Medicine [5] and the Journal of
the American Medical Association [6] have shown that
these psychostimulants do not increase blood pressure nor
the risk of ventricular arrhythmias. According to these
studies, which show the opposite of those formulated by
the FDA, clinical guidelines developed by psychiatrists
decided to perform a clinical screening of each child before
the administration of the psychostimulant. In case of any
clinical suspicion of known cardiac disease, the child
should be referred to a cardiologist for an ECG and
additional cardiac examinations. In a recent paper, David
et al. [7] investigated the efficacy of a combined treatment:
cognitive-behavioral therapy + Atomoxetine vs.
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psychotherapy vs. Atomoxetine for children with
Attention-Deficit/Hyperactivity Disorder (ADHD). They
found that the combined treatment was superior to
medication alone on ADHD symptoms.

Figure 1. The chemical structure of (A) Methylphenidate
and (B) Atomoxetine

Figure 2. The mechanism of action for Atomoxetine

Figure 3. The mechanism of action for Methylphenidate

Discussions
Cardiac arrhythmias in children with Attention Deficit
who have not received any medication
Polanczyk et al. have shown that the parasympathetic
nervous system is not fully developed in children with
attention deficit and hyperactivity, which translates into
lower parasympathetic tone [8]. This may be responsible
for a higher plasma concentration of adrenaline and
norepinephrine, a higher excretion of catecholamines, as
demonstrated by Dvorakova et al. [9] by measuring urinary
catecholamines, increased heart rate, sinus tachycardia,
and atrial or ventricular premature contractions. This
explains why some children with attention deficit may also
suffer from arrhythmias before the beginning of the
treatment with Methylphenidate or Atomoxetine. This
mechanism also explains the beneficial effect of the
administration of beta-blockers when the treatment with
Atomoxetine or Methylphenidate induces atrial or
210

ventricular premature contractions, so that the
psychostimulant treatment can be continued safely.
Considering that the two drugs can increase the
endogenous concentration of catecholamines, we can
explain the arrhythmic effects by a beta-1 adrenergic effect
which increases inotropism and also the heart rate.
Prasad et al. [10] evaluated 5,289 children with
attention deficit hyperactivity disorder with the aim of
identifying arrhythmias that would contraindicate the
administration of Atomoxetine or Methylphenidate. None
of all these children suffered from ECG arrhythmias, so
none of them had any contraindication in the
administration of psychostimulants.
Arrhythmic side effects of Methylphenidate and
Atomoxetine
The first mention of the arrhythmic side effects of
Methylphenidate dates back to 2012, when Schellman et al.
[11] demonstrated a 1.8-fold increased risk of ventricular
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arrhythmias and sudden cardiac death in the adults treated
with Methylphenidate. Although the study was performed
on a large number of individuals, it was non-randomized
and the group in which ventricular arrhythmias were
recorded had the peculiarity that it included many patients
with pre-existing cardiac impairments. One year earlier, in
a large-scale retrospective study including 150,000
individuals, Habel et al. [12] revealed that neither
Methylphenidate nor Atomoxetine increases the risk of
ventricular arrhythmias or the risk of sudden cardiac death.
It is worth mentioning that the two above-mentioned
studies were conducted on the adult population and not on
children.
Two other large studies by the same author, one on
21,000 patients receiving Atomoxetine [13] and another on
44,000 patients receiving Methylphenidate [14], did not
reveal an increased risk of ventricular arrhythmias or
sudden cardiac death after drug administration.
Arj et al. administered Methylphenidate to 141 children
with attention deficit and hyperactivity disorder and found
no ECG changes in arrhythmias or significantly increased
blood pressure levels in these children.
Tanidir et al. [15] administered Atomoxetine to 41
children and monitored them by means of ECG and Holter
ECG. None of these children developed significant
arrhythmias during the follow-up period.
In an experimental study, Scherer et al. [16] showed
that Atomoxetine has the ability to block hERG channels.
This study could not specify whether the blockage of
hERG channels has clinical implications, as it was a study
performed on renal embryonic cells. There are, however,
reports on the prolongation of the QT interval by
Atomoxetine with torsade de pointes in which this drug
was incriminated, but obviously the value of these
publications is small compared to studies performed on
larger populations. Studies that have been performed on
adults show that the short- or long-term administration of
Methylphenidate or Atomoxetine does not increase the risk
of QT prolongation [17-19].
The administration of Methylphenidate and
Atomoxetine to Children with Cardiac Arrhythmias
Buchhorn et al. examined 100 children with Attention
Deficit with and without Hyperactivity, not treated with
drugs. Of these 100 cases, arrhythmias were observed in 9
children: 9 had premature atrial contractions, 4 had
premature ventricular contractions and periods of
accelerated
idioventricular
rhythm.
Accelerated
idioventricular rhythm is considered “physiological
arrhythmia” in children and does not require treatment. Six
of
these
children
with
arrhythmia
received
Methylphenidate and none experienced worsening of the
clinical arrhythmia, therefore Methylphenidate could be
continued for a long period of time.

There are also studies that evaluated the QT interval in
children receiving Atomoxetine. It is worth mentioning
that QT measurement differs from one cardiologist to
another, the best overlapping values being found in
arrhythmologists [20]. Thus, if QT interval measurements
are made by different cardiologists, different values are
obtained. This is the reason why 8.6% of the children who
were administered the placebo drug had increased QT
intervals of 30 ms in the meta-analysis by Wernicke et al
[21].
Another problem with studies reporting medicationrelated arrhythmias is that they do not specify the type of
arrhythmias: benign arrhythmias such as sinus tachycardia,
premature atrial or ventricular contractions, QT
prolongation, or malignant arrhythmias such as ventricular
tachycardia and ventricular fibrillation [22,23]. The
differentiation is important because the risk of sudden
death differs depending on the type of arrhythmia. The
study by Shin et al. [24] revealed a relatively increased risk
of arrhythmias 1.6:1 in methylphenidate users compared to
non-users. It is worth mentioning that there is no reference
to the type of arrhythmia revealed during follow-up. This
is a major drawback of a large study with 1,224 patients
suffering from Attention Deficit and Hyperactivity.
Anamnestic screening for heart disease
This screening can be performed by a psychiatrist and
it requires 3 important questions from the Anamnesis: 1)
Does the child have a family history of sudden cardiac
death? 2) Has the child ever been hospitalized for cardiac
problems or has he undergone heart surgery? and 3) Has
the child ever had palpitations with an increased heart
rate > 180/ min or Syncope? This third question "opens the
door" to other symptoms that can be reported by the patient
such as palpitations that suggest premature beats, without
an increased rate > 180/ min. The reason for this last
question is to eliminate sinus tachycardia that is
“physiological arrhythmia” and does not require any
special attention.
If during Anamnesis, the psychiatrist receives any
positive answer (YES) to any of the 3 questions, a cardiac
consultation should be taken into account. This includes a
clinical examination, an ECG and blood pressure
measurement. During the physical examination, the
cardiologist searches for signs of heart failure: edema,
hepatomegaly, jugular distension, which may be signs of
underlying heart disease. The presence of a heart murmur
"per se" does not contraindicate the administration of
Atomoxetine or Methylphenidate, but the cardiologist
should differentiate between “physiological murmur” and
the murmur caused by an underlying heart disease. A blood
pressure level over 120/70 mmHg before the onset of the
treatment involves regular measurement of the blood
pressure during the treatment, at 1 week initially, then at 1month follow-up. If the ECG examination does not reveal
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Gabriel Cismaru & Viorel Lupu

arrhythmias or prolonged QT interval, the treatment with
Methylphenidate or Atomoxetine may be initiated. If
arrhythmias are present on the initial ECG, treatment can
be started, but it requires reassessment after 1 week and 1
month.
The reassessment estimates arrhythmia follow-up: is
there any aggravation which requires the interruption of the

treatment or is the arrhythmia stable and the treatment can
be maintained? The presence of ventricular arrhythmia
such as extrasystoles, bigeminies, couplets are not an
absolute contraindication to Methylphenidate and
Atomoxetine, but instead, the beta-blocker treatment
should be initiated with re-assessment at 1 week and 1
month (Figure 4).

Figure 4. Algorithm for screening before the beginning of the treatment with Concerta or Straterra

Conclusions

Conflict of interest disclosure

To sum up, the risk of arrhythmic events due to
Methylphenidate and Atomoxetine is extrapolated to
children from studies performed on adults. Indeed,
arrhythmic events were described in adults, some of them
being fatal, especially if a pre-existing heart disease such
as myocardial infarction, chronic pulmonary heart disease,
were present. But these cardiac diseases are not found
among children.
Studies on children have not revealed a clearly
increased arrhythmic risk associated with these drugs.
However, caution is required in the case of children who
are known to have congenital heart disease or
arrhythmogenic cardiomyopathies, and in such cases, a
cardiac examination should be requested and medication
should be administered under close ECG monitoring.
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